Mrityunjay Singh

Mrityunjay Singh

Auto-generated profile, based on publicly available information

Mrityunjay Singh

Computational Biophysics and CADD Group, Computational and Mathematical Biology Centre (CMBC), Translational Health Science and Technology Institute (THSTI)

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2020 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
LMLovika Mittal
Lovika Mittal
AKAnita Kumari
Anita Kumari
MSMitul Srivastava
Mitul Srivastava
MSMrityunjay Singh
Mrityunjay Singh
SAShailendra Asthana
Shailendra Asthana
The pandemic caused by novel coronavirus disease 2019 (COVID-19) infecting millions of populations worldwide and counting, has demanded quick and potential therapeutic strategies. Current approved drugs or molecules under clinical trials can be a good pool for repurposing through in-silico techniques to quickly identify promising drug candidates. The structural information of recently released crystal structures of main protease (Mpro) in APO and complex with inhibitors, N3, and 13b molecules was utilized to explore the binding site architecture through Molecular dynamics (MD) simulations. The stable state of Mpro was used to conduct extensive virtual screening of the aforementioned drug pool. Considering the recent success of HIV protease molecules, we also used anti-protease molecules for drug repurposing purposes. The identified top hits were further evaluated through MD simulations followed by the binding free energy calculations using MM-GBSA. Interestingly, in our screening, several promising drugs stand out as potential inhibitors of Mpro. However, based on control (N3 and 13b), we have identified six potential molecules, Leupeptin Hemisulphate, Pepstatin A, Nelfinavir, Birinapant, Lypression and Octreotide which have shown the reasonably significant MM-GBSA score. Further insight shows that the molecules form stable interactions with hot-spot residues, that are mainly conserved and can be targeted for structure- and pharmacophore-based designing. The pharmacokinetic annotations and therapeutic importance have suggested that these molecules possess drug-like properties and pave their way for in-vitro studies.

28 September 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
MSMitul Srivastava
Mitul Srivastava
CSCharu Suri
Charu Suri
MSMrityunjay Singh
Mrityunjay Singh
RMRajani Mathur
Rajani Mathur
SAShailendra Asthana
Shailendra Asthana
Oncotarget | https://doi.org/10.18632/oncotarget.26136 Mitul Srivastava, Charu Suri, Mrityunjay Singh, Rajani Mathur, Shailendra Asthana Molecular dynamics simulation reveals the possible druggable hotspots of USP7

19 February 2021 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
MSMrityunjay Singh
Mrityunjay Singh
MSMitul Srivastava
Mitul Srivastava
SWSharad R. Wakode
Sharad R. Wakode
SAShailendra Asthana
Shailendra Asthana

26 June 2013 in Beilstein Journal of Organic Chemistry
Verified
Journal Article
Open access
PDF file
ASAshish Sharma
Ashish Sharma
MSMrityunjay Singh
Mrityunjay Singh
NRNitya Nand Rai
Nitya Nand Rai
DSDevesh M. Sawant
Devesh M. Sawant
A practical, mild and efficient protocol for the Pictet–Spengler reaction catalyzed by cyanuric chloride (trichloro-1,3,5-triazine, TCT) is described. The 6-endo cyclization of tryptophan/tryptamine and modified Pictet–Spengler substrates with both electron-withdrawing and electron-donating aldehydes was carried out by using a catalytic amount of TCT (10 mol %) in DMSO under a nitrogen atmosphere. TCT catalyzed the Pictet–Spengler reaction involving electron-donating aldehydes in excellent yield. Thus, it has a distinct advantage over the existing methodologies where electron-donating aldehydes failed to undergo 6-endo cyclization. Our methodology provided broad substrate scope and diversity. This is indeed the first report of the use of TCT as a catalyst for the Pictet–Spengler reaction.

28 January 2022 in RSC Advances
Verified
Journal Article
Open access
PDF file
NPNikil Purushotham
Nikil Purushotham
MSMrityunjay Singh
Mrityunjay Singh
BPBugga Paramesha
Bugga Paramesha
VKVasantha Kumar
Vasantha Kumar
SWSharad Wakode
Sharad Wakode
SAShailendra Asthana
Shailendra Asthana
Owing to its presence in several biological processes, Sirt1 acts as a potential therapeutic target for many diseases. Here, we report the structure-based designing and synthesis of two distinct series of novel Sirt1 inhibitors, benzimidazole mono-peptides and amino-acid derived 5-pyrazolyl methylidene rhodanine carboxylic acid. The compounds were evaluated for in vitro enzyme-based and cell-based Sirt1 inhibition assay, and cytotoxic-activity in both liver and breast cancer cells. The tryptophan conjugates i.e. 13h (IC50 = 0.66 μM, ΔGbind = −1.1 kcal mol−1) and 7d (IC50 = 0.77 μM, ΔGbind = −4.4 kcal mol−1) demonstrated the maximum efficacy to inhibit Sirt1. The MD simulation unveiled that electrostatic complementarity at the substrate-binding-site through a novel motif “SLxVxP(V/F)A” could be a cause of increased Sirt1 inhibition by 13h and 13l over Sirt2 in cell-based assay, as compared to the control Ex527 and 7d. Finally, this study highlights novel molecules 7d and 13h, along with a new key hot-spot in Sirt1, which could be used as a starting lead to design more potent and selective sirtuin inhibitors as a potential anticancer molecule.

9 February 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
SMSaidulu Mattapally
Saidulu Mattapally
MSMrityunjay Singh
Mrityunjay Singh
KMKona Samba Murthy
Kona Samba Murthy
SAShailendra Asthana
Shailendra Asthana
SBSanjay Banerjee
Sanjay Banerjee
Computational modeling suggests impaired interactions between NKX2.5 and GATA4 in individuals carrying a novel pathogenic D16N NKX2.5 mutation Computational modeling suggests impaired interactions between NKX2.5 and GATA4 in individuals carrying a novel pathogenic D16N NKX2.5 mutation